Pipeline

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Five things for pharma marketers to know: Wednesday, December 13, 2017

Five things for pharma marketers to know: Wednesday, December 13, 2017

By

Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH

Five things for pharma marketers to know: Monday, December 11, 2017

Five things for pharma marketers to know: Monday, December 11, 2017

By

Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

By

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

Five things for pharma marketers to know: Monday, December 4, 2017

Five things for pharma marketers to know: Monday, December 4, 2017

By

CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate

The 2018 pipeline report: Aspiring assets to keep an eye on

The 2018 pipeline report: Aspiring assets to keep an eye on

By

The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

Five things for pharma marketers to know: Wednesday, November 29, 2017

Five things for pharma marketers to know: Wednesday, November 29, 2017

By

U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

By

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

Five things for pharma marketers to know: Tuesday, November 14, 2017

Five things for pharma marketers to know: Tuesday, November 14, 2017

By

FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

By

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Five things for pharma marketers to know: Thursday, November 9, 2017

Five things for pharma marketers to know: Thursday, November 9, 2017

By

GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick

Five things for pharma marketers to know: Tuesday, November 7, 2017

Five things for pharma marketers to know: Tuesday, November 7, 2017

By

Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Thursday, October 12, 2017

Five things for pharma marketers to know: Thursday, October 12, 2017

By

Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads

Infographic | How often are drugmakers sharing clinical-trial data?

Infographic | How often are drugmakers sharing clinical-trial data?

The answer: it depends on what phase the trial is in.

Five things for pharma marketers to know: Tuesday, September 12, 2017

Five things for pharma marketers to know: Tuesday, September 12, 2017

By

Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

By

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Why Sanofi's dengue fever vaccine fell short of expectations

Why Sanofi's dengue fever vaccine fell short of expectations

By

Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

By

Merck's CETP inhibitor anacetrapib and Novartis' monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

By

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

By

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Sunday at ASCO: What the latest trial data has to say about precision medicine

Sunday at ASCO: What the latest trial data has to say about precision medicine

By

Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

By

Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.

The immuno-oncology market prepares for the inevitable question: 'What's next?'

The immuno-oncology market prepares for the inevitable question: 'What's next?'

By

This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.

Five things for pharma marketers to know: Friday, May 26, 2017

Five things for pharma marketers to know: Friday, May 26, 2017

By

FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

By

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

By

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

By

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

By

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.